News

A microbial metabolite, isovalerate, and its precursor leucine restored gut barrier function in malnourished mice, a preclinical study found.

A Rutgers-led study finds teens who follow beauty influencers or watch tutorials use significantly more personal care products, many containing endocrine-disrupting chemicals.

Pediatric psychologist Jeff Temple, PhD, explains how pediatricians can help families establish healthy routines and more intentional screen use.

Ravi Jhaveri, MD, says proposed changes to the childhood vaccine schedule lack evidence and could leave vulnerable children unprotected.

Lori Handy, MD, says vaccine conversations with hesitant families should prioritize trust, follow-up, and the benefits for the individual child.

Navigate back-to-school vaccine requirements, evidence, and FAQs—plus the latest measles data and new pneumococcal options for pediatric practice.

Lori Handy, MD, says back-to-school visits give pediatricians an opportunity to revisit vaccines and address questions families encounter online.

A meta-analysis of 190 studies and 2.8 million children pinpoints eczema, delayed allergens, and antibiotics as top food allergy risks.

In 38 late preterm/early-term dyads, breast milk composition shifted by week 8 while maternal gut stayed stable, and infant gut Bifidobacterium rose.

Lisa Swanson, MD, lays out the current JAK inhibitor landscape for pediatric AD.

New approvals and emerging data are expanding nonsteroidal topical treatment options for several chronic pediatric skin conditions.

Adverse childhood experiences may affect pediatric skin disease risk and outcomes, but researchers say evidence remains limited.

Scholar Rock says apitegromab's SMA BLA stays on track for its September 30, 2026, PDUFA date after dropping one of 2 fill-finish sites.

Executive order seeks to trim routine childhood vaccines, split combination shots, and push parent-doctor decisions—sparking debate as measles surges.

Phase 3 SMART data support the safety of clesrovimab in infants and children at increased risk for severe RSV disease across 2 seasons.

Revised Anaphylm packaging cut pouch-opening time from 17 to 3 seconds, and self-administered PK matched clinician-administered data.

A pediatric pain specialist says a dedicated procedure suite helps deliver faster, more individualized chronic pain care while restoring function.

Phase 3 SMART trial found clesrovimab was well tolerated in high-risk infants through 2 RSV seasons, with safety comparable to palivizumab.

A pediatric pain specialist says multidisciplinary care and family engagement are key to restoring function in children with chronic pain.

A collaborative mental health program increased pediatricians' diagnosis, follow-up, and treatment of anxiety and depression in primary care.

A pediatric pain specialist says multidisciplinary care and family engagement are key to restoring function in children with chronic pain.

FDA accepted Merck's sBLA extending ENFLONSIA (clesrovimab-cfor) to high-risk children under 2 in their second RSV season.

An interventional pain specialist says pediatricians can improve outcomes by recognizing chronic pain early and referring children before disability worsens.

A look back at the FDA approvals, regulatory decisions, and pipeline updates in the pediatric health care space from July 2026.

Find out the correct diagnosis of this 19-year-old boy with Down syndrome and progressive loss of communication.

Lisa Swanson, MD, acknowledges that the decision to refer a patient with AD to a dermatologist or allergist is highly individualized, shaped by each pediatric clinician's own comfort level with skin disease.

Lisa Swanson, MD, describes the framework she uses at follow-up visits to judge whether a topical steroid regimen is succeeding.

A look back at the latest clinical trial updates for the pediatric population during July 2026.